Alerts will be sent to your verified email
Verify Email
NGLFINE
|
NGL Fine-Chem
|
Hikal
|
Sequent Scientific
|
|
|---|---|---|---|
|
Operational Metrics
|
|||
|
Pharmaceutical Sector
|
|||
|
Total reactor capacity
|
308.0 kL | 145.0 kL | n/a |
|
R&D as a % of Total Sales
|
1.51 % | 4.01 % | 0.0 |
|
Financials
|
|||
|
5 yr Average ROE
|
18.84 % | 10.48 % | 1.28 % |
|
5yr average Equity Multiplier
|
1.38 | 2.17 | 2.12 |
|
5yr Average Asset Turnover Ratio
|
1.06 | 0.81 | 0.92 |
|
5yr Avg Net Profit Margin
|
12.49 % | 5.87 % | 0.94 % |
|
Price to Book
|
2.29 | 3.67 | 7.01 |
|
P/E
|
30.57 | 51.04 | 225.82 |
|
5yr Avg Cash Conversion Cycle
|
36.59 Days | 33.87 Days | 55.84 Days |
|
Inventory Days
|
49.75 Days | 64.21 Days | 76.26 Days |
|
Days Receivable
|
83.78 Days | 101.46 Days | 87.51 Days |
|
Days Payable
|
82.12 Days | 96.57 Days | 117.98 Days |
|
5yr Average Interest Coverage Ratio
|
24.92 | 4.8 | 2.31 |
|
5yr Avg ROCE
|
25.51 % | 13.73 % | 7.29 % |
|
5yr Avg Operating Profit Margin
|
18.8 % | 16.42 % | 8.58 % |
|
5 yr average Debt to Equity
|
0.17 | 0.68 | 0.5 |
|
5yr CAGR Net Profit
|
38.35 % | -3.79 % | n/a |
|
5yr Average Return on Assets
|
13.85 % | 4.82 % | 0.71 % |
|
Shareholdings
|
|||
|
Promoter Holding
|
72.74 % | 68.85 % | 52.61 % |
|
Share Pledged by Promoters
|
0.0 | 0.0 | 0.0 |
|
Change in Promoter Holding (3 Yrs)
|
-1.07 % | 0.08 % | -0.41 % |
|
Change in Mutual Fund Holding (3 Yrs)
|
0.0 | 2.17 % | 9.92 % |
|
NGL Fine-Chem
|
Hikal
|
Sequent Scientific
|
|
|---|---|---|---|
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|